Degarelix and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Degarelix
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines can affect your heart's rhythm. Buprenorphine (a pain or opioid-dependence medicine) and degarelix (used for prostate cancer) can each stretch out a part of your heartbeat called the QT interval. When two medicines that do this are taken together, the effect can add up, which in rare cases could lead to an irregular heartbeat.
This concern is based on how the drugs work rather than lots of real-world reports, so please don't panic. The risk matters more if you have a heart condition, low potassium or magnesium, or a slow heart rate. Your care team can manage this by checking your heart and choosing the safest plan for you. Talk with your doctor or pharmacist before changing anything.
Effect: Additive QT-interval prolongation with combined buprenorphine and degarelix.
- Mechanism: Both agents independently prolong the QT interval; effect is additive (pharmacodynamic, not PK). Neither is a prodrug relevant here.
- Direction: Increased risk of QTc prolongation and, theoretically, torsades de pointes.
- Evidence: Theoretical; combined risk not quantified. Onset unspecified.
- Management: Avoid concomitant use where possible. If used together, obtain baseline and follow-up ECGs, correct electrolytes (K+, Mg2+), and assess additive risk factors (bradycardia, CHF, baseline QT prolongation, congenital long-QT, recent AF cardioversion, digitalis therapy).
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
The simultaneous administration of buprenorphine with medications that can extend the QT interval should be avoided 342. It remains unknown what risk is posed by pairing buprenorphine with additional agents that prolong QT. When prescribing buprenorphine to patients who have risk factors, these observations warrant consideration in clinical judgment; such risk factors include hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. This is a heart-rhythm caution, and your team can manage it.
- Your prescriber may check an ECG before and during treatment to watch your QT interval.
- They may review your potassium and magnesium levels and correct them if low.
- They may consider whether an alternative is appropriate, especially if you have heart disease, a slow heart rate, or a known long-QT problem.
Tell your pharmacist or doctor about any fainting, dizziness, or fluttering/pounding heartbeat, and share your full medication list so they can tailor your plan.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Degarelix and Buprenorphine together?
Buprenorphine and degarelix can each prolong the QT interval, so combining them may add up and raise the risk of an irregular heartbeat. Providers often avoid the combination or monitor with ECGs and electrolytes, so review your heart risk factors with your care team. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Degarelix and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Degarelix and Buprenorphine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. This is a heart-rhythm caution, and your team can manage it. Your prescriber may check an ECG before and during treatment to watch your QT interval. They may review your potassium and magnesium levels and correct them if low. They may consider whether an alternative is appropriate, especially if you have heart dise… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Degarelix or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: BUTRANS(R) transdermal system patch, buprenorphine transdermal system patch. Purdue Pharma L.P. (per FDA), Stamford, CT, 2016. DailyMed
- Product Information: BELBUCA(TM) buccal film, buprenorphine buccal film. Endo Pharmaceuticals Inc. (per FDA), Malvern, PA, 2016.
- Product Information: BUPRENEX(R) intravenous injection, intramuscular injection, buprenorphine HCl intravenous injection, intramuscular injection. Indivior Inc. (per DailyMed), Richmond, VA, 2016. DailyMed
Keep reading about Buprenorphine
Keep reading about Degarelix
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist